On Nov 06, major Wall Street analysts update their ratings for $Editas Medicine (EDIT.US)$, with price targets ranging from $5 to $13.
Barclays analyst Gena Wang maintains with a hold rating, and maintains the target price at $5.
Oppenheimer analyst Jay Olson maintains with a hold rating.
Stifel analyst Dae Gon Ha maintains with a buy rating, and adjusts the target price from $17 to $11.
Chardan Capital analyst Geulah Livshits maintains with a buy rating, and maintains the target price at $12.
JonesTrading analyst Soumit Roy maintains with a buy rating, and maintains the target price at $13.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The company's third quarter presented incremental progress following its strategic update.
The primary discussion among investors regarding Editas Medicine is centered on the debate if the company's new strategy marks progress or regression. The view is that reni-cel for sickle cell disease and transfusion-dependent thalassemia represents an asset with reduced risk that has potential for monetization. This asset also provides essential insights that could be advantageous as the company evaluates future strategies for their in vivo candidate.
The focus of Editas Medicine on in vivo HSPC editing is still viewed as a more efficient allocation of its expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline update in Q1 2025, along with forthcoming updates on reni-cel BD activity.
The recent quarter is viewed as a supplementary period following a strategic change announced earlier. Editas Medicine has shifted focus towards partnering or out-licensing its leading asset for SCD/BT while concentrating on the development of its in vivo pipeline. The decision to partner SCD/BT is considered strategically appropriate given the class's gradual adoption rate. However, a cautious stance is being maintained until more advancement is seen in the in vivo pipeline.
Here are the latest investment ratings and price targets for $Editas Medicine (EDIT.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
